Navigation Links
Study shows cost-effectiveness of smoking cessation counseling during hospitalization
Date:6/18/2014

OTTAWA, June 18, 2014 In a recent study published in Tobacco Control, researchers at the University of Ottawa Heart Institute have demonstrated the cost-effectiveness of the Ottawa Model for Smoking Cessation (OMSC), an intervention that includes in-hospital counseling, pharmacotherapy and post-hospital follow-up, compared to usual care among smokers hospitalized with acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease.

The study examined patients hospitalized in Ontario, a province with a population of approximately 12.8 million. The smoking prevalence among Ontarians aged 15 years and older was 15.4% in 2009. The smoking prevalence among Canadian hospital populations is higher, at 20%. Consequently, on a given day in Ontario, approximately 6,400 of the province's 32,000 hospital beds are occupied by current smokers. Healthcare is publicly funded through the Ontario Health Insurance Plan, where medically necessary services including primary care and specialty care, hospital stays, diagnostic investigations and surgical procedures are available at no cost to residents. There are 211 hospital sites in Ontario that recorded an estimated 987,757 acute care inpatient admissions in 2009.

The study shows that from the hospital payer's perspective, delivery of the Ottawa Model for Smoking Cessation (OMSC) can be considered cost effective the program costs a mere $20 to help one person quit smoking, $103 to help patients avoid a day spent in hospital, $36 to gain one year of life, and $68 to gain one quality-adjusted (i.e., healthy) year of life. In the first year, the researchers calculated that provision of the OMSC to 15,326 smokers would generate 4,689 quitters, and would prevent 116 re-hospitalizations, 923 hospital days, and 119 deaths. Results were robust within numerous sensitivity analyses. An important consideration is the relatively low intervention cost compared to the reduction in costs related to readmissions for illnesses associated with continued smoking.

"Not surprisingly, these results indicate that the economic burden to the hospital system of continued smoking is significant," said Kerri-Anne Mullen, lead author and Network Manager for OMSC at the University of Ottawa Heart Institute. "Hospitalization is an opportune time to initiate smoking cessation treatment as smokers are frequent and high cost users of the healthcare system and are often highly motivated to quit smoking during their admission."

An estimated $547 million is spent each year in Ontario on hospitalizations for acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease (COPD) alone. The study estimates that provision of the OMSC intervention to smokers admitted with these issues would represent 0.20% of this cost, yet could result in several individual and health system benefits and, in the case of COPD patients, could result in actual cost savings.


'/>"/>

Contact: Vincent Lamontagne
vlamontagne@ottawaheart.ca
613-761-4427
University of Ottawa Heart Institute
Source:Eurekalert

Related medicine news :

1. TGen and Scottsdale Healthcare begin study of new drug for patients with solid tumors
2. Gut bacteria predict survival after stem cell transplant, study shows
3. E-cigs heavily marketed on Twitter, study finds
4. Caffeine affects boys and girls differently after puberty, study finds
5. UTMB to participate in $30 million national study to prevent falls in older people
6. Moffitt study shows utilizing genetic health care professional reduces unnecessary testing
7. Virginia G. Piper Cancer Center vaccine study hopes to improve pancreatic cancer treatment
8. Charity funding study brings alcohol industry influence on UK policy into question
9. New study sheds light on what happens to cool kids
10. Breakthrough study sheds new light on best medication for children with seizures
11. Harvard study finds substance abuse & mental health problems in MSM interfere with HIV medication adherence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... M&S ... Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon M&S's ... standards and specifications such as ANSI, ISO and proven test methods used in ...
(Date:3/27/2017)... PA (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research ... strategy, having the skills needed to execute that strategy, and the actual success ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer ... stages, is more than 95%. Once the cancer spreads to other organs, bones, or ... find out how to avoid this latter group, tune in to Lifestyle Magazine ...
(Date:3/27/2017)... Texas (PRWEB) , ... March 27, 2017 , ... ... at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate ... and will be an opportunity for area-residents to celebrate two great years while ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... TEL AVIV, Israel , March 27, 2017 ... focused on oncology and immunology, announced today that AGI-134, an ... recently announced acquisition of Agalimmune Ltd., will be featured at ... Meeting in Washington, DC to ... ...
Breaking Medicine Technology: